Neurobiology of Addiction

Key Players - Brain's Chemical Crew

• Dopamine (DA): The "pleasure chemical." Central to reward, motivation, and reinforcement. Key in drug-seeking.
• Serotonin (5-HT): Modulates mood, sleep patterns, and impulsivity. Imbalances contribute to craving and relapse.
• GABA (Gamma-aminobutyric acid): Primary inhibitory neurotransmitter. Reduces neuronal excitability; alcohol & sedatives potentiate its effects.
• Glutamate: Main excitatory neurotransmitter. Involved in learning, memory, and addiction-related synaptic plasticity.
• Endogenous Opioids (Endorphins, Enkephalins): Provide natural pain relief and euphoria. Opioid drugs mimic their action.

⭐ Dopamine release in the nucleus accumbens is a common final pathway for the rewarding effects of most drugs of abuse.

Reward Pathway - Pleasure's Superhighway

• Mesolimbic Pathway: Key reward circuit; Dopamine (DA) is main neurotransmitter.
  • Ventral Tegmental Area (VTA): DA synthesis.
  • Nucleus Accumbens (NAc): Reward, pleasure.
  • Prefrontal Cortex (PFC): Craving, compulsion.
• Drug Hijack: All addictive drugs ↑ DA in NAc.
  • Stimulants (cocaine, amphetamine): Block DA reuptake.
  • Opioids: Disinhibit VTA DA neurons.
  • Alcohol, Nicotine, Cannabis: ↑ DA release via various mechanisms.
• NAc DA Receptors:
  • D1: "Go" signal (promotes drug-seeking).
  • D2: "No-Go" signal (signals satiety, inhibits seeking).

⭐ Chronic drug use leads to neuroadaptations like ↓ D2 receptor density in NAc, contributing to anhedonia and compulsive use.

📌 VTA Nudges PFC with Dopamine (Ventral Tegmental Area, Nucleus Accumbens, Prefrontal Cortex, Dopamine).

Adaptation & Tolerance - The New Normal

• Brain adapts to persistent drug presence, establishing a new "normal" state.
• Mechanisms of Tolerance:
  • Pharmacokinetic (Metabolic): ↑ drug metabolism (e.g., enzyme induction by alcohol, barbiturates).
  • Pharmacodynamic (Cellular/Functional): Neuronal adaptation at the drug's site of action.
    • Receptor changes: Downregulation (e.g., for agonists like opioids) or upregulation (for antagonists).
    • Receptor desensitization: ↓ response despite binding.
    • Altered gene expression: e.g., CREB, ΔFosB.
• Allostasis: Shift in hedonic set point; reward pathways become less sensitive (↓ reward), anti-reward systems become overactive.

  ⭐ ΔFosB is a highly stable transcription factor that accumulates with chronic drug exposure, mediating long-lasting neural and behavioral plasticity related to addiction.

Withdrawal Signs - Brain's Payback Time

Withdrawal: Brain's counter-adaptation when drug use ceases.

• Neurochemical Basis: Opponent-process theory.
  • Drug suppresses system → brain upregulates it.
  • Cessation → unopposed hyperactivity (e.g., ↑ noradrenaline in opioid withdrawal).
• Key Brain Regions:
  • Locus Coeruleus (LC): Central to opioid withdrawal (↑ noradrenergic activity).
  • Amygdala: Mediates anxiety, dysphoria.
• Dependence Link:
  • Physical: Body adapts; withdrawal upon cessation.
  • Psychological: Compulsive use, craving.

⭐ Locus Coeruleus hyperactivity (↑ noradrenaline) is a major driver of opioid withdrawal symptoms like anxiety, tremors, and autonomic signs.

Craving & Relapse - Addiction's Echo

• Key Brain Regions:
  • Amygdala: Heightened cue-reactivity, emotional drug memories.
  • Hippocampus: Context-dependent craving (people, places).
  • Prefrontal Cortex (PFC): Impaired judgment, ↓ impulse control, relapse vulnerability.
• Neurobiology:
  • Glutamatergic dysregulation: Underpins intense, persistent craving.
  • Incentive Salience: Cues acquire exaggerated motivational importance ("wanting").

⭐ The amygdala's heightened response to drug cues, coupled with impaired PFC control, forms a critical neurobiological loop driving craving and relapse.

High‑Yield Points - ⚡ Biggest Takeaways

• The mesolimbic pathway (VTA to NAc, PFC) is central, mediating reward and motivation.
• Dopamine (DA) is the primary neurotransmitter for pleasure, reinforcement, and salience.
• Chronic substance use causes neuroadaptations, like ↓ D2 receptor density, leading to tolerance and withdrawal.
• Glutamate system dysregulation, especially in PFC-NAc projections, drives craving and drug-seeking.
• GABAergic system alterations contribute to withdrawal symptoms, anxiety, and loss of control.
• Prefrontal Cortex (PFC) dysfunction results in impaired executive functions like decision-making and impulsivity.
• Stress, acting via the HPA axis and CRF system, significantly increases relapse vulnerability and drug-seeking behavior.